Nedosiran: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nedosiran. Educational only — not medical advice.
Labeled uses
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m2 [see Clinical Pharmacology (12.3 )], Clinical Studies (14.1 )].
Source: FDA labeling via NIH DailyMed (set ace9d4bc…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.